+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ra Pharmaceuticals Inc (RARX) - Financial and Strategic SWOT Analysis Review

  • ID: 4391490
  • SWOT Analysis
  • May 2019
  • 51 pages
  • GlobalData

FEATURED COMPANIES

  • Akari Therapeutics Plc
  • Amgen Inc
  • Bioverativ Inc
  • F. Hoffmann-La Roche Ltd
  • MorphoSys AG
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Ra Pharmaceuticals Inc (RARX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Ra Pharmaceuticals Inc (Ra Pharmaceuticals) is a clinical stage biopharmaceutical company that develops therapeutics for patients with rare diseases based on its Extreme Diversity technology platform. It has pipeline products in pre-clinical, Phase I and Phase II trials for CNS diseases, autoimmune and renal disorders. The company’s lead product candidate, RA101495(Zilucoplan) is a self-administered subcutaneous (SC) injection for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). The company has collaboration with Merck & Co to carry out the pre-clinical programs for dry age-related macular degeneration (AMD), glomerulonephritis (C3GN) and dense deposit disease (DDD). Ra Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

Ra Pharmaceuticals Inc Key Recent Developments

May 09, 2019: Ra Pharmaceuticals reports first quarter 2019 financial results and provides corporate update
Mar 07, 2019: Ra Pharmaceuticals reports fourth quarter and full year 2018 financial results and provides corporate update
Dec 06, 2018: Ra Pharmaceuticals receives development milestone payment under agreement with Merck
Nov 15, 2018: Ra Pharmaceuticals elects Bo Cumbo to Board of Directors
Nov 07, 2018: Ra Pharmaceuticals announces third quarter 2018 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Akari Therapeutics Plc
  • Amgen Inc
  • Bioverativ Inc
  • F. Hoffmann-La Roche Ltd
  • MorphoSys AG
Section 1 - About the Company
  • Ra Pharmaceuticals Inc - Key Facts
  • Ra Pharmaceuticals Inc - Key Employees
  • Ra Pharmaceuticals Inc - Key Employee Biographies
  • Ra Pharmaceuticals Inc - Major Products and Services
  • Ra Pharmaceuticals Inc - History
  • Ra Pharmaceuticals Inc - Company Statement
  • Ra Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 – Company Analysis
  • Company Overview
  • Ra Pharmaceuticals Inc - Business Description
  • Ra Pharmaceuticals Inc - Corporate Strategy
  • Ra Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Ra Pharmaceuticals Inc - Strengths
  • Ra Pharmaceuticals Inc - Weaknesses
  • Ra Pharmaceuticals Inc - Opportunities
  • Ra Pharmaceuticals Inc - Threats
  • Ra Pharmaceuticals Inc - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
  • Ra Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • May 09, 2019: Ra Pharmaceuticals reports first quarter 2019 financial results and provides corporate update
  • Mar 07, 2019: Ra Pharmaceuticals reports fourth quarter and full year 2018 financial results and provides corporate update
  • Dec 06, 2018: Ra Pharmaceuticals receives development milestone payment under agreement with Merck
  • Nov 15, 2018: Ra Pharmaceuticals elects Bo Cumbo to Board of Directors
  • Nov 07, 2018: Ra Pharmaceuticals announces third quarter 2018 financial results
  • Sep 25, 2018: Ra Pharma names Aoife M. Brennan, M.B., B.Ch., to Board of Directors
  • Aug 08, 2018: Ra Pharmaceuticals reports second quarter 2018 financial results
  • May 09, 2018: Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
  • Apr 18, 2018: Ra Pharmaceuticals Names John C. King as Chief Commercial Officer
  • Mar 14, 2018: Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About the Author
  • Contact Us
  • Disclaimer
List of Tables
  • Ra Pharmaceuticals Inc, Key Facts
  • Ra Pharmaceuticals Inc, Key Employees
  • Ra Pharmaceuticals Inc, Key Employee Biographies
  • Ra Pharmaceuticals Inc, Major Products and Services
  • Ra Pharmaceuticals Inc, History
  • Ra Pharmaceuticals Inc, Subsidiaries
  • Ra Pharmaceuticals Inc, Key Competitors
  • Ra Pharmaceuticals Inc, Ratios based on current share price
  • Ra Pharmaceuticals Inc, Annual Ratios
  • Ra Pharmaceuticals Inc, Interim Ratios
  • Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
  • Ra Pharmaceuticals Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Ra Pharmaceuticals Inc, Performance Chart (2014 - 2018)
  • Ra Pharmaceuticals Inc, Ratio Charts
  • Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
Note: Product cover images may vary from those shown

Loading
LOADING...

A selection of companies mentioned in this report includes:

  • Regeneron Pharmaceuticals Inc
  • Novartis Pharmaceuticals Corp
  • MorphoSys AG
  • F. Hoffmann-La Roche Ltd
  • Bioverativ Inc
  • Apellis Pharmaceuticals Inc
  • Amyndas Pharmaceuticals LLC
  • Amgen Inc
  • Alexion Pharmaceuticals Inc
  • Akari Therapeutics Plc
  • Achillion Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll